Treatment choices based on multiplatform profiling platform, unlike those with sequencing alone, do not cause a cost explosion in refractory cancer patients

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/26334

Title:	Treatment choices based on multiplatform profiling platform, unlike those with sequencing alone, do not cause a cost explosion in refractory cancer patients
Authors:	Russell, K. J. JANSSENS, Jaak Dean, A. Hernandez, A. Voss, A.
Issue Date:	2017
Publisher:	ELSEVIER SCIENCE INC
Source:	VALUE IN HEALTH, 20(9), p. A579-A579 (Art N° PMD42)
Notes:	[Russell, K. J.; Hernandez, A.; Voss, A.] Caris Life Sci, Basel, Switzerland. [Janssens, J.] Univ Hasselt, Hasselt, Belgium. [Dean, A.] St John God Hosp, Subiaco, WA, Australia.
Document URI:	http://hdl.handle.net/1942/26334
ISSN:	1098-3015
e-ISSN:	1524-4733
DOI:	10.1016/j.jval.2017.08.1026
ISI #:	000413599901365
Rights:	© 2017 Published by Elsevier Inc.
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

File	Description	Size	Format
russell 2.pdf Restricted Access	Published version	58.92 kB	Adobe PDF	View/Open Request a copy

1

checked on Jun 25, 2024

48

checked on Sep 7, 2022

40

checked on Sep 7, 2022

Check